Verve Therapeutics Inc.

11/16/2024 | Press release | Archived content

Design of Heart 2: A Phase 1b clinical trial of VERVE 102, an in vivo base editing medicine delivered by a GalNAc LNP and targeting PCSK9 to durably lower LDL cholesterol